Summary A humanised IgGl/k version of A33 (hA33) has been constructed and expressed with yields up to 700 mg 1' in mouse myeloma NS0 cells in suspension culture. The equilibrium dissociation constant of hA33 (KD= 1.3 al., 1990, 1994). A phase I/II study has been conducted (Welt et al., 1994) with this murine antibody, in which some tumour responses were observed at the maximum tolerated dose (75 mCi m-2). The major limiting toxicity was haematological, as observed in almost all therapy studies with radioimmunoconjugates. All patients treated developed a human anti-mouse antibody (HAMA) response after one administration, and this led to very rapid clearance of the conjugate upon retreatment, consistent with all previous results with rodent antibodies. These data suggest that A33 is a promising antibody for successful radioimmunotherapy of colon cancer, and the purpose of this study has been to design and develop a second generation reagent based upon it. The key to the development of successful radioimmunotherapy will be the identification of reagents capable of delivering a killing dose to tumour cells without unacceptable toxicity to normal tissues. To this end we are evaluating several alternative radioimmunotherapeutic strategies including the use of isotopes which require internalisation into the cell for cytotoxicity, such as 125I (which are less toxic to normal tissues), and engineering the antibody for the optimal delivery of highly cytotoxic agents such as 90Y.
Tumour localisation and therapy studies have now been performed using a considerable number of antibodies directed to tumour-associated antigens. These studies have demonstrated that uptake of radioimmunoconjugates by human solid tumours is generally very low, rarely exceeding 10% of injected dose per kilogram of tumour, and that therapeutic responses are observed only rarely. Our aim has been to develop a new generation of radioimmunoconjugates for successful treatment of solid tumours, and to this end we have attempted to optimise all aspects of the conjugate -the antibody targeting moiety, therapeutic effector and linkage between the two. We have addressed these issues in the construction and characterisation of novel radioimmunoconjugates for therapy of colorectal cancer metastases based on the antibody A33. This antibody recognises a poorly characterised antigen expressed by virtually all primary and secondary colon cancers.
A33 labelled with '"'I has shown impressive, selective tumour localisation in patients with hepatic metastases of colorectal carcinoma (Welt et al., 1990 (Welt et al., , 1994 . A phase I/II study has been conducted (Welt et al., 1994) with this murine antibody, in which some tumour responses were observed at the maximum tolerated dose (75 mCi m-2). The major limiting toxicity was haematological, as observed in almost all therapy studies with radioimmunoconjugates. All patients treated developed a human anti-mouse antibody (HAMA) response after one administration, and this led to very rapid clearance of the conjugate upon retreatment, consistent with all previous results with rodent antibodies. These data suggest that A33 is a promising antibody for successful radioimmunotherapy of colon cancer, and the purpose of this study has been to design and develop a second generation reagent based upon it. The key to the development of successful radioimmunotherapy will be the identification of reagents capable of delivering a killing dose to tumour cells without unacceptable toxicity to normal tissues. To this end we are evaluating several alternative radioimmunotherapeutic strategies including the use of isotopes which require internalisation into the cell for cytotoxicity, such as 125I (which are less toxic to normal tissues), and engineering the antibody for the optimal delivery of highly cytotoxic agents such as 90Y.
The radioisotope 9'Y has been used in several radioimmunotherapy studies and is an attractive isotope for this purpose owing to its appropriate physical properties. As a pure high-energy P-emitter 9Y has advantages over the more commonly used "''I in terms of greater energy deposited and ease of patient handling. The half-life of 9Y (2.7 days) is sufficient for tumour localisation and short enough to minimise toxicity in organs involved in catabolism. Previous studies with 9'Y have been limited by the use of poor acyclic chelators such as DTPA which allows leakage of 9'Y from the chelator under physiological conditions with subsequently increased bone marrow toxicity (Hnatowich et al., 1988; Larson, 1991) . Attempts to circumvent this problem by the co-administration of free EDTA to chelate free 9Y released have also been made but showed only a very limited improvement (Stewart et al., 1990) . Stable macrocyclic chelators for 9'Y have now been developed based on the macrocycle 12N4 (also known as DOTA), which essentially completely prevents loss of the isotope from the conjugate under physiological conditions (Deshpande et al., 1990; Harrison et al., 1991; DeNardo et al., 1994) .
We Isaacs et al., 1992; Stephens et al., 1994) . Full humanisation involves redesigning the variable domains so that the amino acids contributing to the antigen-binding site of the mouse antibody are integrated into the framework of a human antibody variable region. Several strategies have been employed for full antibody humanisation (reviewed in Mountain and Adair, 1992).
We have recently described the evaluation, in a nude mouse xenograft system, of chemically cross-linked antibody fragments for radioimmunotherapy when labelled with 9Y via the 12N4 macrocycle . In this study we demonstrated the potential targeting advantages of a tri-Fab fragment termed TFM. In this paper we describe the construction, expression and tumour cell binding properties of humanised variants of the antibody A33, together with studies on their biodistribution and pharmacokinetics in animals when labelled with 90Y or "'In. Humanised A33 TFM labelled with 90Y is a promising reagent for therapy of colorectal carcinoma.
Materials and methods
Cloning and expression ofgenes for A33, humanised A33 IgGI and humanised A33 Fab' A33 hybridoma cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum and 1 mM glutamine. Total RNA was prepared from 109 hybridoma cells using guanadinium isothiocyanate and poly(A+) mRNA isolated from this by oligo (dT) affinity chromatography. First strand cDNA was synthesised from 10 mg of mRNA using the Amersham International cDNA synthesis kit. DNA sequences encoding A33 variable domains (including signal sequences for secretion) were amplified from the cDNA using the PCR procedure described by Jones and Bendig (1991) but with primers designed to allow facile cloning of the PCR products into vectors for expression in mammalian cells. These vectors were derived initially from pEE6 (Stephens and Cockett, 1989) . Figure 1 shows final NSO expression vectors. PCR-amplified fragments for the light chain variable domain were cloned between the BstI and SplI sites of pMRRO10, a pEE6 derivative constructed to allow expression of such sequences as kappa chimeric light chains. PCR-amplified fragments for the A33 heavy chain variable domain were cloned between the HindIII and ApaI sites of pMRRO1 1, a pEE6 derivative constructed to allow expression of such sequences as fy-1 chimeric heavy chains. The cloned variable region genes were sequenced by the double-strand dideoxy chain terminating method using T7 DNA polymerase (Sequenase version 2.0, United States Biochemical, Cleveland, OH, USA).
The humanised variable domains were assembled by the procedure of Daugherty et al. (1991) , using primers which allowed facile cloning into pMRR01O and pMRR01 1 for the light and heavy chains respectively. These humanised variable region genes were sequenced by the same procedures used for the murine variable region genes. An expression vector for the hA33 Fab'Acys heavy chain with a single hinge thiol was constructed by replacing the y-1 constant domains with the appropriate segment from the cB72.3 Fab'Acys gene described by King et al. (1994) . Fab'Acys in NSO cells.
vectors into CHO-L761h cells as described previously (Cockett et al., 1990 After dialysis and ultrafiltration hA33 Fab'Acys was crosslinked to DFM and TFM using the maleimide-based homobifunctional and homotrifunctional linkers CT52 and CT998 respectively, as described for cB72.3 Fab'Acys . These cross-linkers contain the 12N4 macrocycle for incorporation of 'Y. The DFM and TFM produced were purified by gel filtration using a Sephacryl S-200HR column (Pharmacia). Radiolabelling with 'Y was performed as described previously .
Antigen binding assays These were performed using cells of two human colorectal tumour cell lines which express the A33 antigen, Colo2O5 and SW1222. These cells were cultured in DMEM containing 2 mM glutamine and 10% fetal calf serum (Gibco). Assembled antibody in culture supernatants and in purified preparations was quantitated in an ELISA (Whittle et al., 1987) . Direct binding of murine and humanised antibodies to SW1222 cells was measured in a FACScan assay. SW1222 cells were trypsinised to remove them from culture flasks, washed with phosphate-buffered saline (PBS) and resuspended in PBS containing 10% bovine serum and 0.1% sodium azide. Humanised A33 antibody was serially diluted in PBS containing 10% FCS and 0.1% sodium azide and added to 2 x 105 cells. Following a 1 h incubation on ice the cells were washed in PBS and then incubated with a rhodamine anti-(human Fc) conjugate (1:1000 in PBS, 10% FCS and 0.1% sodium azide) for a further 1 h on ice. After washing in PBS, the amount of rhodamine-labelled A33 antibody conjugate bound to the cells was measured in a FACScan analyser (Becton-Dickinson). Direct binding of murine A33 was measured by FACScan analysis after incubation of SW1222 cells with FITC-labelled antibody. Suitable non-specific antibody controls were carried out to demonstrate that A33 binds specifically via antibody-antigen interaction rather than non-specifically through Fc interactions.
Determination of affinities of murine and humanised antibodies was based on the procedure described by Krause et al. (1990 Radiolabelling and animal studies Antibodies were labelled with 9Y via the macrocyclic ligand tetra-azocyclododecane tetra-acetic acid, (termed 12N4 or DOTA) coupled to the immunoglobulin via 12N4-maleimide linkers (Harrison et al., 1991) as previously described . Radiolabelling of hA33-12N4 conjugates with 9Y and 125I, and biodistribution studies in nude mice bearing subcutaneous SW1222 tumour xenografts were carried out also as described . Antibodies were labelled with "'In via a second macrocyclic ligand, 1,4,7-triazacyclononane triacetic acid or 9N3 using 9N3-maleimide linkers as described previously was in the blood circulation and this was taken to be the case for humans. Calculations were made based on the assumptions that the pharmacokinetics of "'In-and 'Y-labelled antibodies are the same as each other and the same in monkeys and humans, also that there is no specific uptake of radiolabelled antibodies in the marrow so that the radioactivity in the blood and marrow are the same after a few (<5) h. To generate numbers representative of humans the following data for standard man were used: a total blood volume of 5000ml; marrow spaces, absorbed fractions for 'Y P-particles and the thickness of the endosteal layer were taken from Whitwell and Spiers (1976) . Owing to the high energy of the 90Y P-particles, the radiation absorbed doses in the marrow and the endosteal layer are for all practical purposes the same.
Results
Cloning of A33 variable region genes DNA sequences encoding the light and heavy chain variable domains were amplified by PCR from cDNA prepared from mRNA isolated from the A33 hybridoma and cloned into vectors allowing expression as a chimeric IgG1. Direct binding assays were performed on culture supernatants following transient co-expression of the heavy and light chains. The antigen recognised by A33 is poorly characterised and has not been isolated, so all binding assays used a human colorectal tumour cell line. The results of these binding assays showed that the chimeric antibody bound to cells expressing the antigen as well as murine A33 (data not shown), confirming that the cloned genes correspond to those of A33. Figure 2 shows the amino acid sequences of the heavy and light chains deduced from the DNA sequence of the cloned variable domain genes. N-terminal protein sequencing of the first 11 amino acids gave results completely consistent with these deduced amino acid sequences for both heavy and light chains, confirming the appropriate genes had been cloned.
Humanisation of A33
The 'y-I isotype was chosen for the humanised heavy chain because this isotype best matches the murine -y-2a of the parent antibody. Antibodies with either human -y-1 or murine y-2a heavy chains are able to fix complement (CDC) and mediate cellular cytotoxicity (ADCC) via interaction with FcRI on phagocytic mononuclear cells (Burton and Woof, 1992). The murine variable regions of A33 were humanised according to the strategy described by Adair et al. (1991) . This strategy involves using as frameworks heavy and light chains with the greatest overall homology to the murine antibody, and transferring into these frameworks all the residues from the murine antibody predicted to be involved in antigen binding. The VH of A33 shows closest homology (70%) to the consensus sequence of human subgroup VHIII, while the VL shows greatest homology to the consensus sequence of human subgroups VLI and VLIV (62%). From these subgroups LAY, which has a VHIII heavy chain and VLI light chain, was chosen as the human framework. Figure 2 shows the amino acid sequences of the humanised light and heavy chains. For the light chain residues 1-23, 35-45, 47-49, 57-86, 88 and 98-108 Figure 3 shows SDS-PAGE analysis of the purified antibodies under non-reducing conditions. It demonstrates that the purified hIgG was homogeneous and fully assembled. High-performance liquid chromatography (HPLC) analysis also demonstrated it was free of aggregates (data not shown). As expected the hFab'Acys was recovered largely in the form of monovalent Fab' with little in the form of F(ab')2, consistent with results for other recombinant Fab' fragments . Cross-linking of Fab'Acys to TFM was achieved with a yield of 60-65%, as shown by HPLC analysis in Figure 4 . SDS-PAGE analysis of the purified TFM (Figure 3) showed a single species of approximately 150kDa under non-reducing conditions. Figure 5 shows of dehalogenation of the radioiodinated antibody (Brown et al., 1987) .
A series of experiments was performed to compare the biodistribution and pharmacokinetics of hA33 IgG, DFM and TFM. It was consistently observed that humanised TFM and all other humanised fragments examined clear aberrantly quickly from the circulation of mice, far more quickly than the equivalent murine fragments. This phenomenon was shown to be specific to mice and did not occur in rats, guinea pigs or monkeys (data not shown). Figure 9 shows a comparison of biodistribution for hA33 IgG, DFM and TFM in guinea pigs. It demonstrates the more rapid blood clearance of the DFM and TFM, with blood activities falling to 0.01 and 0.02% i.d. g-' respectively at the 144 h time point. Blood activity for hIgG was much higher, at 0.4% i.d. g-1, at this time point. Figure 9 demonstrates very clearly that for DFM much higher levels of radioactivity are taken up by the kidney than for IgG and TFM. This high activity for the DFM clears much more slowly from the kidney than from the blood. At early time points kidney levels were a little higher for TFM than IgG but much lower than for DFM, and the activity cleared much faster from the kidney for TFM than for DFM. These results for A33 are consistent with the view that the kidney is the major organ of clearance for TFM.
The pharmacokinetics of hA33 IgG, TFM and DFM were compared in cynomolgus monkeys. Owing to safety considerations, these components were labelled with "'In rather than 9Y, previous work having suggested that 9Y-labelled IgG and fragments show pharmacokinetics and biodistribution very similar to those labelled with "'In (data not shown). The plasma clearance profiles are shown in Figure   10 with the alpha and beta phase half-life values in Table I . As expected from pharmacokinetic data in mice and guinea pigs both TFM and DFM cleared faster from the circulation than IgG. In addition, DFM cleared more quickly than TFM. When plasma clearance was examined without decay correction for the isotope (Table II) the data was most consistent with monophasic kinetics for IgG and TFM, with biphasic kinetics for DFM. Dosimetric calculations based on these data suggest that when labelled with 9'Y at equivalent amounts of radioactivity injected, the DFM would give approximately a 5-fold lower absorbed dose to the bone marrow than IgG, while TFM would give a 2-fold lower absorbed dose (Table II) .
Discussion
In general, the antibodies directed to tumour-associated antigens that are currently available have been produced from rodent hybridomas and are immunogenic in man. This has been a major obstacle to radioimmunotherapy, since although the first doses of some immunoconjugates have given promising biodistribution and partial therapeutic responses, subsequent doses have been rendered ineffective by rapid clearance due to the HAMA response elicited (Welt et al., 1990; Mountain and Adair, 1992) .
We constructed the humanised variant of A33 by substituting into the frameworks of the human antibody LAY all the residues of the murine antibody, which we predict may contribute to antigen binding. These residues comprise the CDRs together with two residues on the light chain and five on the heavy chain which may contribute to the precise positioning of the CDRs for antigen binding (Adair et al., 1991) . Scatchard analysis suggested the murine and humanised variants of the antibody have equivalent affinity for the antigen on the surface of colorectal tumour cells.
As yet there are still few data concerning the effectiveness of full humanisation in overcoming the patient immune response to rodent antibodies. In three reports on the immunogenicity of humanised antibodies in monkeys (Hakimi et al., 1991; Singer et al., 1993; Stephens et al., 1994 ) the immune response was much reduced compared with the parent murine antibodies. In each case, an anti-idiotype response (i.e. directed to the CDRs) developed on repeat dosing. In the case studied in greatest detail (Stephens et al., 1994 ) the CDRs appear less immunogenic when presented in the human framework since the anti-idiotype response to the humanised antibody was greatly reduced compared with the anti-idiotype component of the immune response to the murine antibody. As yet there are only three reports on the administration of fully humanised antibodies to patients. Two of these studies concerned the humanised antibody CAMPATH-1H. Two non-Hodgkin lymphoma patients treated with 1-20mg doses of this antibody for up to 43 days showed no anti-CAMPATH-lH response during the course of treatment (Hale et al., 1988) . These results should not be over-interpreted, however, because such patients are somewhat immunocompromised before treatment and because the treatment itself is likely to be immunosuppressive. More recently, however, results have become available for eight rheumatoid arthritis patients repeatedly administered with 4-8 mg doses of CAMPATH-1H over 10 days (Isaacs et al., 1992) . Significant clinical benefit was seen in seven of the patients, and anti-CAMPATH-IH antibodies were not detectable in any of the patients after this one course of treatment. Of four patients given a second course of treatment, three showed a detectable anti-CAMPATH-IH response. No data are yet available concerning the nature of this response, whether it interferes with efficacy, and if so, whether such interference can be overcome using larger doses. The immune response to the humanised anti-tumour necrosis factor antibody CDP571 has been examined after administration of single doses of 0.1-10 mg kg-' to human volunteers (Stephens et al., 1994) . Administration of the lower doses led to the development of a weak anti-idiotype response, predominantly of the IgM isotype. Anti-CDP571 antibodies were very low or undetectable after administration of the higher doses. The limited clinical data available for fully humanised antibodies therefore suggest they will show substantially longer half-lives and greatly reduced immunogenicity compared with murine antibodies.
As described previously (Harrison et al., 1991 ) the 12N4 macrocycle gives extremely stable chelation of 9Y, with no significant escape of the isotope in vivo. The potential immunogenicity of the macrocycle, however, as well as that of the humanised antibody carrier is a significant issue. It is far from clear whether macrocyclic chelators are likely to be immunogenic in patients. Kosmas et al. (1992) reported the rapid development of an anti-macrocycle immune response in ovarian cancer patients administered with antibody conjugates carrying 9Y or "'In in the macrocycle p-nitrobenzyl-DOTA. Curiously, administration conditions favouring immunogenicity (i.p. injection of relatively large doses with a high proportion of aggregates) led to a stronger immune response to the macrocycle than to the antibody carrier, and some of these patients manifested symptoms of serum sickness. More recently Watanabe et al. (1994) have examined the immunogenicity of a similar chelator in rabbits, and concluded that an anti-macrocycle response develops in animals injected with the macrocycle conjugated to immunogenic carrier proteins such as murine antibodies, but not in those injected with rabbit antibody conjugates. Studies by Kosmas et al. (1992) to characterise the anti-macrocycle response in patients concluded that it is predominantly directed to the DOTA ring structure itself rather than to the linker, which contains an aromatic ring. We have conducted a study to examine the immunogenicity of the 12N4 macrocycle in mice. The only major difference between the chelator used in these studies and that used by Kosmas et al. (1992) is the presence of the aromatic ring on the latter. The results (TS Baker et al., manuscript in preparation) were similar to those of Watanabe et al. (1994) , in that no anti-macrocycle response could be detected in mice injected with the macrocycle conjugated to a mouse antibody even using conditions very favourable to effective immunisation. Mice injected with the macrocycle conjugated to an immunogenic protein such as a chimeric antibody developed an immune response with components directed to both the carrier protein and the macrocycle. We conclude it is unlikely that immunogenicity of the 12N4 macrocycle will prove to limit the effectiveness of humanised antibodies carrying 9Y administered at reasonable doses intravenously.
Uptake of the 9Y-labelled humanised antibody by human colorectal xenografts in nude mice was similar to that reported for murine A33 labelled with 9Y via the same methodology (P Antoniw et al., manuscript in preparation). This high tumour uptake augurs well for the prospects of achieving therapeutically effective radiation doses in colorectal cancer patients. 9Y continued to accumulate in the tumour for the humanised antibody throughout the 144 h after injection over which measurements were made. This continued accumulation was also observed for hA33 with both of the other colorectal tumour cell lines studied (P Antoniw et al., unpublished) . hA33 labelled with 1251 shows less accumulation, and the increased retention of 9Y by the tumour cells may result from the inability of the macrocyclic chelator to egress from the cells after internalisation.
Clinical studies with chimeric and humanised antibodies have also suggested that these antibodies have a substantially longer circulating half-life than murine antibodies. Humanised antibodies for radioimmunotherapy may therefore deliver an increased dose to the bone marrow from the circulating conjugate, which would give decreased therapeutic ratios unless tumour uptake is correspondingly increased. The production of TFM is an attempt to circumvent this problem. The binding avidity of TFM is increased compared with IgG and pharmacokinetic studies show faster blood clearance in both guinea pigs and cynomolgus monkeys. The mean betaphase half-life of the IgGI in cynomolgus monkeys (129 h) is in the range previously observed for humanised antibodies in this species (Hakimi et al., 1991; Singer et al., 1993; Stephens et al., 1994) . The mean beta-phase half-life for TFM in cynomolgus monkeys (53.7 h) is less than half that of IgG, and dosimetric calculations indicate that for an equivalent injected dose of 9Y this shorter half-life would give an approximately 2-fold benefit for TFM in terms of the radiation dose to the bone marrow. Since the latter is usually the dose-limiting toxicity in clinical studies with therapeutic radioimmunoconjugates, it is likely TFM would allow a higher maximum tolerated dose.
Unlike all other antibody fragments carrying metallic isotopes which have been examined (see for example Sharkey et al., 1990 ) the TFM does not lead to high-level accumulation of the isotope in the kidney or other non-specific tissues. In the present studies DFM showed faster blood clearance and projected bone marrow doses lower than those for both IgG and TFM, but is clearly not an acceptable vehicle for delivering 9Y because it leads to unacceptably high accumulation of this isotope in the kidney. Such kidney accumulation does not occur for DFM labelled with radioiodine (data not shown), and it is likely that the DFM is the most appropriate delivery vehicle for therapy with '3'I.
Clinical success with radioimmunotherapy has so far largely been restricted to haematological malignancies such as lymphomas and leukaemias. hA33 TFM carrying 9Y in the 1 2N4 macrocycle represents one of the first attempts to optimise all components of a radioimmunoconjugate for treatment of solid tumours. Evaluation of this second generation immunoconjugate in colorectal cancer patients may reveal new potential for radioimmunotherapy of solid tumours. As the first stage in clinical evaluation of this technology, a quantitative biodistribution study in colorectal cancer patients using hA33 TFM carrying "'In is in progress.
